Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
22 août 2022 07h00 HE | Travere Therapeutics, Inc.
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Report Second Quarter 2022 Financial Results
28 juil. 2022 16h30 HE | Travere Therapeutics, Inc.
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
16 mai 2022 07h00 HE | Travere Therapeutics, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
15 déc. 2021 07h00 HE | Travere Therapeutics, Inc.
Treatment with highest dose pegtibatinase led to a clinically meaningful 55% mean reduction in total homocysteine from baseline and was generally well-tolerated after 12 weeks of treatment Results...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis
07 sept. 2021 08h00 HE | Travere Therapeutics, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug...
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
16 nov. 2020 08h00 HE | Retrophin, Inc.
New name reflects dedication to patient-inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s shares to trade under new ticker symbol TVTX on...